IRIS
IACOBELLI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.727
EU - Europa 5.926
AS - Asia 5.783
SA - Sud America 749
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 4
Totale 21.285
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.584
SG - Singapore 2.445
CN - Cina 1.547
UA - Ucraina 971
IE - Irlanda 851
GB - Regno Unito 762
RU - Federazione Russa 692
SE - Svezia 639
BR - Brasile 623
TR - Turchia 605
FR - Francia 595
IT - Italia 581
VN - Vietnam 480
DE - Germania 370
IN - India 284
FI - Finlandia 220
BD - Bangladesh 85
CA - Canada 78
HK - Hong Kong 64
PL - Polonia 53
AR - Argentina 44
BE - Belgio 44
IQ - Iraq 43
JP - Giappone 43
MX - Messico 43
KR - Corea 32
ZA - Sudafrica 32
NL - Olanda 29
ES - Italia 27
CZ - Repubblica Ceca 22
UZ - Uzbekistan 21
AT - Austria 19
PK - Pakistan 17
EC - Ecuador 16
ID - Indonesia 16
VE - Venezuela 16
LT - Lituania 13
CO - Colombia 12
IR - Iran 12
EG - Egitto 11
EU - Europa 11
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
IL - Israele 10
PE - Perù 10
MA - Marocco 9
PY - Paraguay 9
UY - Uruguay 9
JO - Giordania 8
PH - Filippine 8
AL - Albania 7
CH - Svizzera 7
CL - Cile 7
KE - Kenya 7
TN - Tunisia 7
AZ - Azerbaigian 6
GR - Grecia 5
NP - Nepal 5
DO - Repubblica Dominicana 4
JM - Giamaica 4
LB - Libano 4
MY - Malesia 4
PT - Portogallo 4
RO - Romania 4
SN - Senegal 4
AO - Angola 3
AU - Australia 3
DZ - Algeria 3
ET - Etiopia 3
HU - Ungheria 3
KG - Kirghizistan 3
OM - Oman 3
RS - Serbia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BH - Bahrain 2
BO - Bolivia 2
CR - Costa Rica 2
GE - Georgia 2
HN - Honduras 2
NG - Nigeria 2
NI - Nicaragua 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
GD - Grenada 1
GT - Guatemala 1
GY - Guiana 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MK - Macedonia 1
ML - Mali 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
Totale 21.279
Salva come PNG Salva come JPEG
Città #
Singapore 1.811
Jacksonville 1.062
Chandler 1.053
San Jose 1.030
Dublin 844
Southend 558
Ashburn 466
Dallas 411
Princeton 385
Beijing 344
Izmir 329
Nanjing 307
Los Angeles 235
Santa Clara 223
The Dalles 189
Cambridge 177
Wilmington 177
Council Bluffs 175
Ho Chi Minh City 150
Tongling 140
Boardman 134
Ann Arbor 127
New York 127
Buffalo 113
Nanchang 111
Dearborn 105
Hanoi 101
Altamura 91
Moscow 87
Chieti 66
Munich 62
Woodbridge 62
São Paulo 61
Hong Kong 54
Hebei 53
Shenyang 50
Orem 46
Tianjin 46
Brussels 43
Pescara 43
Kunming 42
Houston 39
Tokyo 38
Redondo Beach 37
Brooklyn 34
Chennai 33
Denver 32
Stockholm 32
Montreal 30
Seoul 30
Warsaw 30
Boston 29
Jiaxing 29
London 29
Atlanta 27
Chicago 26
Norwalk 26
Dong Ket 24
Poplar 24
Rome 24
Hangzhou 23
Hefei 23
Johannesburg 23
Nuremberg 23
Changsha 22
Helsinki 21
Manchester 20
Tashkent 20
Da Nang 19
Falls Church 19
Frankfurt am Main 19
Kocaeli 19
Grevenbroich 18
Turku 18
Brno 17
Montesilvano 17
Baghdad 16
Collecorvino 16
Haiphong 16
Milan 16
San Francisco 16
St Louis 16
Washington 16
Phoenix 15
Rio de Janeiro 15
San Mateo 15
Amsterdam 14
Belo Horizonte 14
Hyderabad 14
Jinan 14
Kraków 14
Lanzhou 14
Mexico City 14
Orange 14
Augusta 13
Leawood 13
Mumbai 13
Ankara 11
Auburn Hills 11
Campinas 11
Totale 12.925
Salva come PNG Salva come JPEG
Nome #
90K (Mac-2 BP) in human milk 236
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 211
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 184
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 182
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 180
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 176
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 172
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. 169
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 167
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 166
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 166
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 166
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 162
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 161
ERBB3 BINDING ANTIBODY 161
Prognostic relevance of LGALS3BP in human colorectal carcinoma 159
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 158
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 155
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 152
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 151
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 151
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 151
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 150
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 149
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 148
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 148
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 147
Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants 147
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 145
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 144
New Targets for Therapy in Pancreatic Cancer 144
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 144
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 142
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 140
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 135
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 135
Novel inhibitors of pvhl-elongin c binding 135
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 134
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 133
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 132
A Stochastic Model for the HIV/AIDS Dynamic Evolution 132
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 132
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 132
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 130
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 129
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 128
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 127
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 127
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 127
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 126
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. 124
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 123
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 123
DNA ploidy and S-phase fraction in pulmonary carcinoids. 121
Tumor-derived microvesicles: The metastasomes. 121
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 121
Prognostic value of 90K protein in HIV infection 120
Surgical treatment of adrenal metastases from non small cell lung cancer 120
[Hairy cell leukemia: prognosis and treatment] 120
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 120
Tyrosine kinase inhibitors 120
Axillary Lymph Node Nanometastases are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients 119
Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. 119
Role of 90K protein in asthma and TH2-type cytokine expression. 117
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 117
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 117
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 117
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 116
Unknown primary tumors 116
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 115
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 115
LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth 114
Prognostic value of a novel circulating serum 90K antigen in breast cancer 114
Increased levels of soluble P-selectin in hypercholesterolemic patients 114
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 114
Prognostic value of gender and primary tumor location in metastatic colon cancer 114
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 113
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 113
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 112
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma 111
Elevated Plasma Levels of 90K (Mac-2 BP) Immunostimulatory Glycoprotein in HIV-1-Infected Children 111
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 111
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 111
Combinations of biological response modifiers: rationale and clinical responses. 110
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 110
A stochastic model for evaluating the HIV anti-retroviral treatment patient cost: a case study 110
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 109
Combined therapy in pancreatic cancer 109
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. 109
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 109
HCV genotype and serum 90K levels: host and virus related factors predict response to a-ifn therapy 108
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 108
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 108
Phospholipase Cgamma1 is required for metastasis development and progression 108
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma 107
Oral etoposide and platinum derivates in the treatment of metastatic Merkel cell carcinoma: report of three cases 107
A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. 106
Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies 105
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study. 105
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1 104
Totale 13.263
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.214
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.214
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202161 0 0 0 0 0 0 0 0 0 0 0 61
2021/2022739 11 12 5 137 90 16 15 52 65 14 93 229
2022/20232.806 210 288 173 356 315 597 159 220 329 25 73 61
2023/20241.213 109 37 99 58 67 356 261 39 14 23 16 134
2024/20253.627 200 751 610 90 64 97 124 189 320 186 402 594
2025/20266.677 553 358 707 796 572 491 1.119 374 672 619 324 92
Totale 21.685